Related Experiment Videos
[Dacarbacine (DTIC) in the therapy of a malignant disease. A review (author's transl)]
Abstract:
Indications and results are reviewed with regard to recent data on the effect of DTIC in patients with malignant melanoma, soft tissue sarcomas, Hodgkin's disease, gastrointestinal carcinomas and oat cell cancer of the lung. Whilst this drug induced--mainly partial--remissions in 25% of the patients with melanomas, it is generally used in other malignant conditions in combination with other cytoxic agents. In soft tissue sarcomas adriamycin appeared as the principal additional drug. In patients with Hodgkin's disease resistant to MOPP treatment and requiring additional cytotoxic drugs, combination chemotherapy including DTIC may induce remissions in more than half of these patients. Other schedules were, however, also effective and results in this difficult group of patients are discussed and compared. In gastrointestinal and in oat cell carcinomas cytotoxic protocols including DTIC have shown some effect, perhaps comparable to other combinations usually employed in these conditions.
Insights
Dacarbazine (DTIC) shows efficacy in malignant melanoma, inducing partial remissions in 25% of patients. It is often combined with other agents for sarcomas, Hodgkin
Area of Science:
- Oncology
- Pharmacology
- Medical Chemistry
Context:
- Review of recent data on the efficacy of Dacarbazine (DTIC).
- DTIC's role in treating various advanced cancers.
- Exploration of DTIC's use as a monotherapy and in combination regimens.
Purpose:
- To assess the indications and outcomes of Dacarbazine (DTIC) in diverse malignancies.
- To evaluate DTIC's effectiveness in malignant melanoma, soft tissue sarcomas, Hodgkin's disease, gastrointestinal carcinomas, and oat cell lung cancer.
- To compare DTIC-inclusive combination chemotherapy regimens.
Summary:
- Dacarbazine (DTIC) achieved partial remissions in 25% of malignant melanoma patients.
- In soft tissue sarcomas, DTIC is frequently combined with Adriamycin.
- For MOPP-resistant Hodgkin's disease, DTIC-based combination chemotherapy yields remissions in over 50% of patients.
- DTIC-containing protocols show some effect in gastrointestinal and oat cell carcinomas, comparable to other standard combinations.
Impact:
- Highlights DTIC's established role in melanoma treatment.
- Demonstrates DTIC's utility as a component in combination therapies for refractory cancers.
- Provides insights into optimizing chemotherapy strategies for difficult-to-treat malignancies.